Sandoz family foundation has offered $3 billion worth of
Novartis shares which has stirred the market.
Altrius Capital Management Inc. has increased its holdings in
Novartis. Despite some shareholders selling their Novartis shares,
Novartis seems to be a strong momentum stock due to its performance in Q4 earnings where it managed to outpace the consensus. Recently,
Novartis acquired
Anthos Therapeutics in a $3.1 bn deal and also entered a licensing agreement with
PTC Therapeutics, making it a recommended investment according to UBS and hedge funds. However,
Morgan Stanley and UBS have recently cut Novartis stock rating, with UBS lowering its price target.
Novartis has also upped its yearly outlook, but shares fell following the disappointing report on
Pluvicto. It also plans to present advancements at upcoming congresses. All these incidences have reflected positively on the
Novartis stock profile making it a strong growth and value stock.
Novartis Stocks News Analytics from Thu, 18 Jul 2024 07:00:00 GMT to Sat, 01 Mar 2025 12:09:38 GMT -
Rating 7
- Innovation 4
- Information 5
- Rumor -6
